At Olema Oncology, we leverage our deep understanding of endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance with the goal of transforming the standard of care for women living with cancer by focusing on developing more convenient and effective therapies. Join us as we aim to design therapies for improving lives.
Total raised: $139M
Founded date: 2007
Investors 4
| Date | Name | Website |
| 19.11.2020 | Logos Capi... | logoscapit... |
| 13.07.2025 | Foresite C... | foresiteca... |
| - | Avoro Capi... | avorocapit... |
| 25.12.2024 | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.10.2020 | Series C | $85M | - |
| 22.07.2020 | Series B | $54M | - |
Mentions in press and media 14
| Date | Title | Description |
| 28.10.2025 | San Francisco is making a comeback. So are these stocks from the City by the Bay | Monday - Friday, 2:00 - 3:00 PM ET San Francisco is on the comeback, which led CNBC to spend a few days to broadcast “Power Lunch” from the network’s stunning studios in the city. Ahead of this special programming, I sought to find the comp... |
| 25.11.2024 | Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors | ROCKVILLE, Md. and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily ... |
| 11.03.2024 | Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update | - |
| 11.03.2024 | Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update | Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 Initiated OPERA-01 pivotal Phase 3 monotherapy trial in Q4 2023; top-line results... |
| 06.03.2024 | Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors | - |
| 04.03.2024 | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted t... |
| 01.10.2020 | Olema Oncology Raises $85M in Series C Financing | Olema Oncology, a San Francisco, CA-based clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, closed an $85m Series C financing. The round was led b... |
| 24.07.2020 | Olema Oncology Scores $54M in Series B | SAN FRANCISCO, CA, Olema Oncology announced the closing of an oversubscribed $54 million Series B financing. >> Click here for more funding data on Olema Oncology >> To export Olema Oncology funding data to PDF and Excel, cl... |
| 23.07.2020 | Olema Oncology Secures $54 Million To Advance Lead Program In Breast Cancer | Olema Oncology — a biopharmaceutical company that is developing innovative targeted therapies for women’s cancers — announced that it has closed an oversubscribed $54 million Series B financing Olema Oncology — a biopharmaceutical company t... |
| 22.07.2020 | Olema Oncology grabs $54M for breast cancer program | Olema Oncology, a biotech focused on women’s cancers, raised $54 million to push its lead program into the clinic and boost its R&D efforts in other areas. Sponsored by Agilent Technologies How would you like to win free bench space at ... |
Show more